Pancreatic Cancer Research

ResearcherHospital of the University of PennsylvaniaActive in the last 2 years

Kim A. Reiss

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-0774-9914; OpenAlex author ID A5000177032, A5104332585. Sources: OpenAlex.

Their work

Papers
34 (first author 5, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2018: 3 papers · 2019: 2 papers · 2020: 4 papers · 2021: 7 papers · 2022: 7 papers · 2023: 3 papers · 2024: 4 papers · 2025: 2 papers · 2026: 2 papers

Papers 34

  1. Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Tria… Co-author DOI 10.1001/jamaoncol.2026.0870↗
  2. Sequential platinum and PARP Inhibition enhances PD1 immunotherapy efficacy in murine Brca2 mutated pancreatic cancer. Co-author DOI 10.1038/s41598-026-35423-7↗
  3. Treatment Innovations in Pancreatic Cancer: Putting Patient Priorities First. Co-author DOI 10.1200/edbk-25-473204↗
  4. Integration of Germline Genetic Testing Into Routine Clinical Practice for Patients With Pancreatic Adenocarcinoma. Co-author DOI 10.1200/op.24.00356↗
  5. Targeting BRCA and PALB2 in Pancreatic Cancer. First author DOI 10.1007/s11864-023-01174-0↗
  6. Cancer-associated fibroblasts maintain critical pancreatic cancer cell lipid homeostasis in the tumor microenvironment. Co-author DOI 10.1016/j.celrep.2024.114972↗
  7. Circulating KRAS G12D but not G12V is associated with survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41467-024-49915-5↗
  8. KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-23-0519↗
  9. Analysis of BRCA1- and BRCA2-Related Pancreatic Cancer and Survival. Last author DOI 10.1001/jamanetworkopen.2023.45013↗
  10. The Clinical Implications of Reversions in Patients with Advanced Pancreatic Cancer and Pathogenic Variants in BRCA1, BRCA2, or PALB2 after Progression on Ruca… Last author DOI 10.1158/1078-0432.ccr-23-1467↗
  11. Advancements in Systemic Therapy for Pancreatic Cancer. First author DOI 10.1200/edbk_397082↗
  12. Cost-Effectiveness of a Risk-Tailored Pancreatic Cancer Early Detection Strategy Among Patients With New-Onset Diabetes. Co-author DOI 10.1016/j.cgh.2021.10.037↗
  13. PARPis and Other Novel, Targeted Therapeutics in Pancreatic Adenocarcinoma. First author DOI 10.1016/j.hoc.2022.07.007↗
  14. Niraparib plus nivolumab or niraparib plus ipilimumab in patients with platinum-sensitive advanced pancreatic cancer: a randomised, phase 1b/2 trial. Co-author DOI 10.1016/s1470-2045(22)00369-2↗
  15. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Co-author DOI 10.1186/s13148-022-01367-8↗
  16. Multianalyte Prognostic Signature Including Circulating Tumor DNA and Circulating Tumor Cells in Patients With Advanced Pancreatic Adenocarcinoma. Co-author DOI 10.1200/po.22.00060↗
  17. A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial). Last author DOI 10.1245/s10434-022-11917-2↗
  18. Correction: THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28127↗
  19. Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. Last author DOI 10.1093/jncics/pkaa121↗
  20. Concurrent Nab-paclitaxel and Radiotherapy: Novel Radiosensitization for Borderline Resectable or Unresectable Pancreatic Cancer. Co-author DOI 10.1097/coc.0000000000000854↗
  21. PARP Inhibitors in Pancreatic Cancer. First author DOI 10.1097/ppo.0000000000000554↗
  22. Alternatives to Perpetual Chemotherapy for Metastatic Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-0612↗
  23. Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, B… Co-author DOI 10.1200/jco.21.00003↗
  24. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.18632/oncotarget.28099↗
  25. Determinants of Homologous Recombination Deficiency in Pancreatic Cancer. First author DOI 10.3390/cancers13184716↗
  26. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Co-author DOI 10.1002/pds.4993↗
  27. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation. Last author DOI 10.1038/s41416-019-0582-7↗
  28. Evaluation of Cyclophosphamide/GVAX Pancreas Followed by Listeria-Mesothelin (CRS-207) with or without Nivolumab in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-3978↗
  29. Opportunity Costs of Receiving Palliative Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1200/jop.19.00328↗
  30. Effect of Gemcitabine and nab-Paclitaxel With or Without Hydroxychloroquine on Patients With Advanced Pancreatic Cancer: A Phase 2 Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2019.0684↗
  31. Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline BRCA or PALB2 Mutation. Last author DOI 10.1200/po.18.00271↗
  32. A phase I dose escalation trial of nab-paclitaxel and fixed dose radiation in patients with unresectable or borderline resectable pancreatic cancer. Co-author DOI 10.1007/s00280-018-3519-6↗
  33. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1078-0432.ccr-17-3668↗
  34. Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. Co-author DOI 10.1200/po.17.00152↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mark H. O’Hara · 14 shared papers, 2018–2026 · strength 2.10
  2. Susan M. Domchek · 10 shared papers, 2018–2026 · strength 1.53
  3. Robert H. Vonderheide · 7 shared papers, 2020–2026 · strength 1.24
  4. Katherine L. Nathanson · 7 shared papers, 2018–2026 · strength 1.02
  5. Timothy J. Brown · 4 shared papers, 2021–2026 · strength 0.98
  6. Peter James O'Dwyer · 9 shared papers, 2018–2024 · strength 0.98
  7. Max Miller Wattenberg · 4 shared papers, 2020–2026 · strength 0.76
  8. Ben Z. Stanger · 3 shared papers, 2024–2026 · strength 0.75
  9. Thomas Benjamin Karasic · 6 shared papers, 2019–2024 · strength 0.74
  10. Jacob Edward Till · 5 shared papers, 2021–2024 · strength 0.66
  11. Erica L. Carpenter · 5 shared papers, 2021–2024 · strength 0.66
  12. Ronac Mamtani · 5 shared papers, 2019–2023 · strength 0.66
  13. Ben Boursi · 4 shared papers, 2020–2023 · strength 0.58
  14. Shun Yu · 5 shared papers, 2018–2021 · strength 0.52
  15. Zain M. Hannan · 3 shared papers, 2021–2026 · strength 0.51
  16. Gregory Lawrence Beatty · 3 shared papers, 2020–2026 · strength 0.48
  17. Sriram R. Anbil · 1 shared paper, 2024 · strength 0.46
  18. William Joseph Chapin · 2 shared papers, 2022 · strength 0.45
  19. Bishal Gyawali · 1 shared paper, 2025 · strength 0.37
  20. Kevin C. Soares · 1 shared paper, 2025 · strength 0.37
  21. Robert J. Torphy · 1 shared paper, 2025 · strength 0.37
  22. Minh T. Than · 1 shared paper, 2024 · strength 0.31
  23. Talia Golan · 2 shared papers, 2020–2023 · strength 0.30
  24. Yu‐Xiao Yang · 2 shared papers, 2020–2022 · strength 0.27
  25. John C. McVey · 1 shared paper, 2026 · strength 0.26

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.